WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today issued its 2013 global corporate responsibility report. The report, available at www.merckresponsibility.com, focuses on the company’s corporate responsibility activities, progress and performance during 2013 in four priority areas where Merck is positioned to have a positive impact: Access to Health, Environmental Sustainability, Employees and Ethics and Transparency.
Highlights from the 2013 report include:
- Reached more than 340 million people through our major programs and partnerships to help address barriers to access
- Continued to work with partners to help ensure that infants and girls in the poorest countries have access to our vaccines
- Through our ground-breaking partnership to treat river blindness, Colombia became the first country to eliminate the disease
- Working in close collaboration with more than 75 implementing partners, Merck for Mothers initiated more than 50 projects in 30 countries
- Implemented a new streamlined environmental strategy that focuses on the issues that are most important to our business and our stakeholders
- Narrowed our environmental sustainability goals to the critical few that align with our business and focus on key global environmental challenges
- Leveraged the scientific and business skills of our employees through the Richard T. Clark Fellowship for World Health to help address the health needs of underserved populations
- Recognized for the 11th consecutive year as a Top 50 Company for Diversity by DiversityInc
- Ranked No.1 in the CPA-Zicklin Index of Corporate Political Disclosure and Accountability for three consecutive years
Merck continues to use several external guidelines and measurement frameworks to inform the scope of its reporting, including the Global Reporting Initiative (GRI G4) Guidelines, the Millennium Development Goals, the Access to Medicine Index and the United Nations Global Compact.
In addition to the comprehensive report at www.merckresponsibility.com, Merck has published an executive summary highlighting various programs and partnerships that exemplify the company’s corporate responsibility commitments. The executive summary is available at www.merckresponsibility.com and www.merckcr.com.
Future information will be provided through a Twitter conversation at #BeWell.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).